This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): Desogestrel and Ethinyl estradiol
Description: Mircette is a combination oral contraceptive consisting of 0.15 mg desogestrel and 0.03 mg ethinyl estradiol. It inhibits Gonadotropin to prevent ovulation.
Deal Structure: In December 2005, Barr Pharmaceuticals, Organon USA and Organon (Ireland), business units of Akzo Nobel NV, and Savient Pharmaceuticals announced that Barr and its subsidiaries have finalized an agreement to acquire the exclusive rights to Organon's Mircette.
Schering-Plough and Organon
In November 2007, Schering-Plough completed the acquisition of Organon BioSciences N.V. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007. Schering-Plough acquired Organon BioSciences from Akzo Nobel N.V. for approximately euro 11 billion in cash.
Teva and Barr
In December 2008, Teva closed its acquisition of Barr.
Merck and Shering-Plough
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement,...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc. Horizon Pharma plc
Pink Sheet Barr to launch generic Mircette
Pink Sheet Organon Mircette
Additional information available to subscribers only: